{"pmid":32464097,"title":"Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19.","text":["Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19.","Coronavirus disease 2019 (COVID-19) is a global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Without approved antiviral therapeutics or vaccines to this ongoing global threat, type I and type III interferons (IFNs) are currently being evaluated for their efficacy. Both the role of IFNs and the use of recombinant IFNs in two related, highly pathogenic coronaviruses, SARS-CoV and MERS-CoV, have been controversial in terms of their protective effects in the host. In this review, we describe the recent progress in our understanding of both type I and type III IFN-mediated innate antiviral responses against human coronaviruses and discuss the potential use of IFNs as a treatment strategy for COVID-19.","Cell Host Microbe","Park, Annsea","Iwasaki, Akiko","32464097"],"abstract":["Coronavirus disease 2019 (COVID-19) is a global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Without approved antiviral therapeutics or vaccines to this ongoing global threat, type I and type III interferons (IFNs) are currently being evaluated for their efficacy. Both the role of IFNs and the use of recombinant IFNs in two related, highly pathogenic coronaviruses, SARS-CoV and MERS-CoV, have been controversial in terms of their protective effects in the host. In this review, we describe the recent progress in our understanding of both type I and type III IFN-mediated innate antiviral responses against human coronaviruses and discuss the potential use of IFNs as a treatment strategy for COVID-19."],"journal":"Cell Host Microbe","authors":["Park, Annsea","Iwasaki, Akiko"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32464097","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.chom.2020.05.008","topics":["Treatment","Mechanism"],"weight":1,"_version_":1668079521320927232,"score":9.490897,"similar":[{"pmid":32360182,"title":"Antiviral activities of type I interferons to SARS-CoV-2 infection.","text":["Antiviral activities of type I interferons to SARS-CoV-2 infection.","There is an urgent need to identify antivirals to curtail the COVID-19 pandemic. Herein, we report the sensitivity of SARS-CoV-2 to recombinant human interferons alpha and beta (IFNalpha/beta). Treatment with IFN-alpha or IFN-beta at a concentration of 50 international units (IU) per milliliter reduces viral titers by 3.4 log or over 4 log, respectively, in Vero cells. The EC50 of IFN-alpha and IFN-beta treatment is 1.35 IU/ml and 0.76 IU/ml, respectively, in Vero cells. These results suggest that SARS-CoV-2 is more sensitive than many other human pathogenic viruses, including SARS-CoV. Overall, our results demonstrate the potential efficacy of human Type I IFN in suppressing SARS-CoV-2 infection, a finding which could inform future treatment options for COVID-19.","Antiviral Res","Mantlo, Emily","Bukreyeva, Natalya","Maruyama, Junki","Paessler, Slobodan","Huang, Cheng","32360182"],"abstract":["There is an urgent need to identify antivirals to curtail the COVID-19 pandemic. Herein, we report the sensitivity of SARS-CoV-2 to recombinant human interferons alpha and beta (IFNalpha/beta). Treatment with IFN-alpha or IFN-beta at a concentration of 50 international units (IU) per milliliter reduces viral titers by 3.4 log or over 4 log, respectively, in Vero cells. The EC50 of IFN-alpha and IFN-beta treatment is 1.35 IU/ml and 0.76 IU/ml, respectively, in Vero cells. These results suggest that SARS-CoV-2 is more sensitive than many other human pathogenic viruses, including SARS-CoV. Overall, our results demonstrate the potential efficacy of human Type I IFN in suppressing SARS-CoV-2 infection, a finding which could inform future treatment options for COVID-19."],"journal":"Antiviral Res","authors":["Mantlo, Emily","Bukreyeva, Natalya","Maruyama, Junki","Paessler, Slobodan","Huang, Cheng"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32360182","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.antiviral.2020.104811","keywords":["antiviral therapy","covid-19","innate immune","interferon","sars-cov-2"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138495505137667,"score":287.2344},{"pmid":32403318,"title":"Porcine Epidemic Diarrhea Virus and the Host Innate Immune Response.","text":["Porcine Epidemic Diarrhea Virus and the Host Innate Immune Response.","Porcine epidemic diarrhea virus (PEDV), a swine enteropathogenic coronavirus (CoV), is the causative agent of porcine epidemic diarrhea (PED). PED causes lethal watery diarrhea in piglets, which has led to substantial economic losses in many countries and is a great threat to the global swine industry. Interferons (IFNs) are major cytokines involved in host innate immune defense, which induce the expression of a broad range of antiviral effectors that help host to control and antagonize viral infections. PEDV infection does not elicit a robust IFN response, and some of the mechanisms used by the virus to counteract the host innate immune response have been unraveled. PEDV evades the host innate immune response by two main strategies including: (1) encoding IFN antagonists to disrupt innate immune pathway, and (2) hiding its viral RNA to avoid the exposure of viral RNA to immune sensors. This review highlights the immune evasion mechanisms employed by PEDV, which provides insights for the better understanding of PEDV-host interactions and developing effective vaccines and antivirals against CoVs.","Pathogens","Li, Shasha","Yang, Jinping","Zhu, Zixiang","Zheng, Haixue","32403318"],"abstract":["Porcine epidemic diarrhea virus (PEDV), a swine enteropathogenic coronavirus (CoV), is the causative agent of porcine epidemic diarrhea (PED). PED causes lethal watery diarrhea in piglets, which has led to substantial economic losses in many countries and is a great threat to the global swine industry. Interferons (IFNs) are major cytokines involved in host innate immune defense, which induce the expression of a broad range of antiviral effectors that help host to control and antagonize viral infections. PEDV infection does not elicit a robust IFN response, and some of the mechanisms used by the virus to counteract the host innate immune response have been unraveled. PEDV evades the host innate immune response by two main strategies including: (1) encoding IFN antagonists to disrupt innate immune pathway, and (2) hiding its viral RNA to avoid the exposure of viral RNA to immune sensors. This review highlights the immune evasion mechanisms employed by PEDV, which provides insights for the better understanding of PEDV-host interactions and developing effective vaccines and antivirals against CoVs."],"journal":"Pathogens","authors":["Li, Shasha","Yang, Jinping","Zhu, Zixiang","Zheng, Haixue"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32403318","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.3390/pathogens9050367","keywords":["coronavirus","immune evasion","innate immunity","porcine epidemic diarrhea virus","type i ifn"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666802845642391552,"score":270.17288},{"pmid":32459003,"title":"A Role for Retinoids in The Treatment of Covid-19?","text":["A Role for Retinoids in The Treatment of Covid-19?","The 2020 global outbreak of the novel coronavirus (SARS-CoV-2 or Covid-19) is a serious threat to international health and thus there is an urgent need for discovery of novel therapies or use of repurposed drugs that can make a significant impact on slowing the spread of the virus. Type 1 interferons (IFN-I) are a family cytokines of the early innate immune response to viruses that are being tested against SARS-CoV-2. However coronaviruses similar to SARS-CoV-2 can suppress host IFN-I anti-viral responses. Retinoids are a family molecules related to vitamin A that possess robust immune modulating properties, including the ability to increase and potentiate the actions of IFN-I. Therefore adjuvants such as retinoids, capable of increasing IFN-I mediated anti-viral responses should be tested in combinations of IFN-I and anti-viral drugs in pre-clinical studies of SARS-CoV-2.","Clin Exp Pharmacol Physiol","Trasino, Steven E","32459003"],"abstract":["The 2020 global outbreak of the novel coronavirus (SARS-CoV-2 or Covid-19) is a serious threat to international health and thus there is an urgent need for discovery of novel therapies or use of repurposed drugs that can make a significant impact on slowing the spread of the virus. Type 1 interferons (IFN-I) are a family cytokines of the early innate immune response to viruses that are being tested against SARS-CoV-2. However coronaviruses similar to SARS-CoV-2 can suppress host IFN-I anti-viral responses. Retinoids are a family molecules related to vitamin A that possess robust immune modulating properties, including the ability to increase and potentiate the actions of IFN-I. Therefore adjuvants such as retinoids, capable of increasing IFN-I mediated anti-viral responses should be tested in combinations of IFN-I and anti-viral drugs in pre-clinical studies of SARS-CoV-2."],"journal":"Clin Exp Pharmacol Physiol","authors":["Trasino, Steven E"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32459003","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/1440-1681.13354","keywords":["covid-19","ifn-i","rig-i","sars-cov-2","interferons","retinoids","vitamin a"],"e_drugs":["Retinoids","Vitamin A"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667967698839011328,"score":257.73712},{"pmid":32333818,"title":"COVID-19: lambda interferon against viral load and hyperinflammation.","text":["COVID-19: lambda interferon against viral load and hyperinflammation.","Coronavirus Disease 2019 (COVID-19), triggered by the betacoronavirus SARS-CoV-2, has become one of the worst pandemics of our time that has already caused more than 183,470 deaths [JHU data-23/04/2020, https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9 ecf6]. Effective therapeutic approaches are urgently needed to reduce the spread of the virus and its death toll. Here, we assess the possibility of using interferon lambda (IFNlambda), a third type of interferon sharing low homology with type I IFNs and IL-10, for treating COVID-19 patients. We discuss the unique role of IFNlambda in fine-tuning antiviral immunity in the respiratory tract to achieve optimal protection and minimal host damage and review early evidence that SARS-CoV-2 may impair IFNlambda induction, leading to a delayed type I IFN-dominated response that triggers hyperinflammation and severe disease. We also consider the potential windows of opportunity for therapeutic intervention with IFNlambda and potential safety considerations. We conclude that IFNlambda constitutes a promising therapeutic agent for reducing viral presence and hyperinflammation in a single shot to prevent the devastating consequences of COVID-19 such as pneumonia and acute respiratory distress syndrome (ARDS).","EMBO Mol Med","Andreakos, Evangelos","Tsiodras, Sotirios","32333818"],"abstract":["Coronavirus Disease 2019 (COVID-19), triggered by the betacoronavirus SARS-CoV-2, has become one of the worst pandemics of our time that has already caused more than 183,470 deaths [JHU data-23/04/2020, https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9 ecf6]. Effective therapeutic approaches are urgently needed to reduce the spread of the virus and its death toll. Here, we assess the possibility of using interferon lambda (IFNlambda), a third type of interferon sharing low homology with type I IFNs and IL-10, for treating COVID-19 patients. We discuss the unique role of IFNlambda in fine-tuning antiviral immunity in the respiratory tract to achieve optimal protection and minimal host damage and review early evidence that SARS-CoV-2 may impair IFNlambda induction, leading to a delayed type I IFN-dominated response that triggers hyperinflammation and severe disease. We also consider the potential windows of opportunity for therapeutic intervention with IFNlambda and potential safety considerations. We conclude that IFNlambda constitutes a promising therapeutic agent for reducing viral presence and hyperinflammation in a single shot to prevent the devastating consequences of COVID-19 such as pneumonia and acute respiratory distress syndrome (ARDS)."],"journal":"EMBO Mol Med","authors":["Andreakos, Evangelos","Tsiodras, Sotirios"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32333818","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.15252/emmm.202012465","keywords":["covid-19","cytokine storm","hyperinflammation","interferon","viral infection"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138493945905152,"score":239.76372},{"pmid":32364527,"title":"Immune environment modulation in pneumonia patients caused by coronavirus: SARS-CoV, MERS-CoV and SARS-CoV-2.","text":["Immune environment modulation in pneumonia patients caused by coronavirus: SARS-CoV, MERS-CoV and SARS-CoV-2.","Currently, we are on a global pandemic of Coronavirus disease-2019 (COVID-19) which causes fever, dry cough, fatigue and acute respiratory distress syndrome (ARDS) that may ultimately lead to the death of the infected. Current researches on COVID-19 continue to highlight the necessity for further understanding the virus-host synergies. In this study, we have highlighted the key cytokines induced by coronavirus infections. We have demonstrated that genes coding interleukins (Il-1alpha, Il-1beta, Il-6, Il-10), chemokine (Ccl2, Ccl3, Ccl5, Ccl10), and interferon (Ifn-alpha2, Ifn-beta1, Ifn2) upsurge significantly which in line with the elevated infiltration of T cells, NK cells and monocytes in SARS-Cov treated group at 24 hours. Also, interleukins (IL-6, IL-23alpha, IL-10, IL-7, IL-1alpha, IL-1beta) and interferon (IFN-alpha2, IFN2, IFN-gamma) have increased dramatically in MERS-Cov at 24 hours. A similar cytokine profile showed the cytokine storm served a critical role in the infection process. Subsequent investigation of 463 patients with COVID-19 disease revealed the decreased amount of total lymphocytes, CD3+, CD4+, and CD8+ T lymphocytes in the severe type patients which indicated COVID-19 can impose hard blows on human lymphocyte resulting in lethal pneumonia. Thus, taking control of changes in immune factors could be critical in the treatment of COVID-19.","Aging (Albany NY)","Yao, Zhixian","Zheng, Zhong","Wu, Ke","Junhua, Zheng","32364527"],"abstract":["Currently, we are on a global pandemic of Coronavirus disease-2019 (COVID-19) which causes fever, dry cough, fatigue and acute respiratory distress syndrome (ARDS) that may ultimately lead to the death of the infected. Current researches on COVID-19 continue to highlight the necessity for further understanding the virus-host synergies. In this study, we have highlighted the key cytokines induced by coronavirus infections. We have demonstrated that genes coding interleukins (Il-1alpha, Il-1beta, Il-6, Il-10), chemokine (Ccl2, Ccl3, Ccl5, Ccl10), and interferon (Ifn-alpha2, Ifn-beta1, Ifn2) upsurge significantly which in line with the elevated infiltration of T cells, NK cells and monocytes in SARS-Cov treated group at 24 hours. Also, interleukins (IL-6, IL-23alpha, IL-10, IL-7, IL-1alpha, IL-1beta) and interferon (IFN-alpha2, IFN2, IFN-gamma) have increased dramatically in MERS-Cov at 24 hours. A similar cytokine profile showed the cytokine storm served a critical role in the infection process. Subsequent investigation of 463 patients with COVID-19 disease revealed the decreased amount of total lymphocytes, CD3+, CD4+, and CD8+ T lymphocytes in the severe type patients which indicated COVID-19 can impose hard blows on human lymphocyte resulting in lethal pneumonia. Thus, taking control of changes in immune factors could be critical in the treatment of COVID-19."],"journal":"Aging (Albany NY)","authors":["Yao, Zhixian","Zheng, Zhong","Wu, Ke","Junhua, Zheng"],"date":"2020-05-05T11:00:00Z","year":2020,"_id":"32364527","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.18632/aging.103101","keywords":["covid-19","sars-cov-2","cytokine storm"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138495984336897,"score":229.74245}]}